Form 4: Akero Therapeutics CEO Andrew Cheng Sells Shares Under 10b5-1 Plan

Akero Therapeutics CEO Andrew Cheng sold a total of 30,000 shares of common stock on January 27, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Akero Therapeutics CEO Andrew Cheng sold 24,242 shares at a weighted average price of $54.56, 2,381 shares at a weighted average price of $55.53, and 3,377 shares at a weighted average price of $56.89 on January 27, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan established on August 16, 2024.
• Following these sales, Mr. Cheng directly owns 716,062 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by an executive under a pre-arranged plan. It is neither particularly positive nor negative.

Risks

• The sale of shares by a high-ranking executive could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to manage their stock sales and avoid insider trading allegations.
• The reported transactions are consistent with standard SEC reporting requirements for insider stock sales.
• Comparable companies in the biotech sector also regularly disclose similar Form 4 filings for their executives.

Stakeholder Impact

• The stock sales may have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Akero Therapeutics, Andrew Cheng, insider trading, stock sale, Form 4, Rule 10b5-1, executive stock sale